Both GLP-1 and GIP can protect synapses and cognition
JMCP 27(3):354366 Trogdon JG, Finkelstein EA, Hylands T, Dellea PS, Kamal-Bahl SJ (2008) Indirect costs of obesity: a review of the current literature
The SELECT trial, published in the New England Journal of Medicine in 2023, demonstrated that semaglutide significantly reduced major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity, representing a landmark finding for GLP-1 receptor agonists in cardiovascular risk reduction
Interestingly, a recent study utilizing Brattleboro rats, a model of hereditary hypothalamic diabetes insipidus, revealed an augmented response to centrally administered GLP-1 RAs, leading to a greater reduction in fluid intake compared to wildtype rats [7]
Common food sensitivities include gluten, sugar, soy, corn, shellfish, peanuts, and dairy
Note that upper arm injections typically require assistance from another person, as specified in the product Instructions for Use